Question · Panya answer

Is semax actually worth trying as a nootropic?

Russian-trial-validated for stroke recovery (approved as a medicine there). Nootropic / focus claims are extrapolation, supported by Russian clinical use but thinner Western evidence. Often paired with selank for anxiolytic balance. Safety profile clean. Honest read: cognitive support plausible, transformative is overhyped.

Last reviewed · Panya.health editorial

What semax actually is

Semax is a synthetic 7-amino-acid analog of ACTH(4-7), developed by the Russian Academy of Sciences in the 1980s and approved as a medicine in Russia and CIS countries for ischemic stroke recovery and neurological rehabilitation. Mechanism work from Myasoedov, Kost, and Levitskaya's groups: semax upregulates BDNF and NGF expression in the hippocampus and cortex, modulates dopaminergic and serotonergic transmission, and influences enkephalin / endorphin pathways. The neurotrophic-factor angle is the most-cited mechanism behind its nootropic claims; the dopamine / endorphin angle is more often cited for the focus / motivation effects users report.

What the evidence actually shows

Russian Phase 2/3 trials in ischemic stroke recovery showed faster neurological function recovery and reduced disability scores at 30 days vs placebo (Gusev 1997; later replications). The trials are real but the regulatory rigor is different from FDA / EMA standards, and most published work is in Russian journals. For nootropic / cognitive-enhancement claims in healthy adults, the evidence is thinner: small open-label trials and mechanism extrapolation. Animal studies consistently show pro-cognitive effects in rodents (improved spatial memory, attention, stress resistance). Subjective reports from the Western nootropic community: increased focus, mild mood lift, anxiolytic counterweight when paired with caffeine or amphetamine-class stimulants. The honest framing: the stroke-recovery case has trial data; the focus-and-mood case is 'plausible based on mechanism + Russian clinical use, not Western-validated.'

Practical use

Approved Russian protocol: nasal spray, 0.1 percent or 1 percent solution depending on indication, multiple drops per nostril daily for 7 to 14 days. Off-label community practice: 250 to 1000 mcg per day intranasal (lower concentration for daily nootropic use, higher for acute focus sessions). Effects begin within 30 to 60 minutes and last 4 to 8 hours per session-dose. Often paired with selank (semax in the morning for activation, selank in the evening or as needed for anxiolytic counterweight). Reconstitution into nasal spray formulation is community knowledge; subcutaneous injection works but bioavailability + first-pass to brain is worse than intranasal for this molecule. Cycles of 2 to 4 weeks with breaks; continuous use risks tolerance.

Where Panya stands

Semax is documented at panya.health/peptide/semax with mechanism, Russian + Western evidence comparison, and dosing community practice. Panya does NOT yet route to vendors for semax because non-GLP-1 vendor scoring is gated on lawyer review. The Russian-imported brand product (Innopharm Semax) is occasionally available through specialty channels in EU markets; otherwise the research-chem channel dominates. Selank is documented separately at panya.health/peptide/selank and the GH-stack peptide page covers a different cognitive territory; the natural compound-stack pairing is semax + selank rather than semax + GH-stack.

Your specific match

The answer for your situation.

The answer above is the general case. The match for your specific profile, region, budget, and urgency comes from our 2-minute quiz. One email, your match, no list.

We earn a small commission when you buy through recommended vendors. That is how this stays free. Vendors rank by quality signals, not paid placement.